Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

Senior Management Appointments

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce two senior management appointments.

Stephen Symonds has joined the Company as its new Chief Financial Officer and is expected to join the board in due course.  Stephen is an experienced finance professional and was until recently the Chief Financial Officer of Envigo, a private equity backed provider of pre-clinical services for the pharmaceutical industry, where he spent eight years.  Prior to that, Stephen spent a decade with KPMG, working on a wide-ranging portfolio of clients.  Earlier in his career, he built a broad experience in a variety of small to medium-size accounting companies and as the finance lead in a family-owned business.

The board would like to thank Nick Walters for providing the Company with interim financial leadership while the Chief Financial Officer recruitment process was conducted.

Francesca Cormack has been appointed as the Company's Chief Scientist, having spent seven years at Cambridge Cognition, most recently as Director of Research and Innovation.  Francesca will lead the Company's research and development activities and act as the Company's scientific leader, with a view to enhancing its competitive position and supporting its long-term business success.  She is also an honorary senior research fellow at Cambridge University's department of psychiatry.

Jenny Barnett, currently Chief Scientific Officer, will be stepping down from the Company at the end of April 2022 to focus her efforts on Monument Therapeutics.  Monument Therapeutics was spun out from Cambridge Cognition in July 2021 and continues to work closely with the Company using its cognitive assessments as core elements of their developments.

For further information, contact:

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com